Sandy Macrae - 25 May 2026 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Reporting relationship: PRESIDENT, CEO AND DIRECTOR, Director
Issuer ticker: SGMO
Reported as of: 25 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 May 2026, 19:30:05 UTC
Prior SEC filing: 03 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Willoughby, Attorney-in-Fact

Key filing fact

Sandy Macrae filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 27 May 2026.

Key facts

This page summarizes Sandy Macrae's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 May 2026, 19:30.

Change

Previous filing in this sequence was filed on 03 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001675687 Primary reporting owner

Macrae Sandy

Relationship: PRESIDENT, CEO AND DIRECTOR, Director
Address: C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND
Signature: /s/ Scott Willoughby, Attorney-in-Fact
Signature date: 27 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGMO transaction

Common Stock

Tax liability

Transaction value
Shares: -12,613
Change %: -0.66%
Price: $0.1743^*
Shares after: 1,895,043
Date: 25 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Footnote F2

Includes: 22,543 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 246,094 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.